Lördag 30 Augusti | 20:59:36 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-11-05 08:00 Kvartalsrapport 2026-Q3
2026-08-27 08:00 Kvartalsrapport 2026-Q2
2026-05-21 N/A Årsstämma
2026-05-13 08:00 Kvartalsrapport 2026-Q1
2026-02-19 08:00 Bokslutskommuniké 2025
2025-11-05 08:00 Kvartalsrapport 2025-Q3
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-23 - X-dag ordinarie utdelning ONCO 0.00 SEK
2025-05-22 - Årsstämma
2025-05-15 - Kvartalsrapport 2025-Q1
2025-02-27 - Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-14 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-05-23 - X-dag ordinarie utdelning ONCO 0.00 SEK
2024-05-22 - Årsstämma
2024-04-15 - Extra Bolagsstämma 2024
2024-02-27 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-10 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning ONCO 0.00 SEK
2023-05-25 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-09-23 - Extra Bolagsstämma 2022
2022-08-11 - Kvartalsrapport 2022-Q2
2022-06-28 - Årsstämma
2022-05-20 - X-dag ordinarie utdelning ONCO 0.00 SEK
2022-05-04 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-24 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning ONCO 0.00 SEK
2021-05-26 - Årsstämma
2021-05-26 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-12-04 - Extra Bolagsstämma 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning ONCO 0.00 SEK
2020-05-26 - Årsstämma
2020-05-26 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-12-17 - Extra Bolagsstämma 2019
2019-11-19 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-22 - X-dag ordinarie utdelning ONCO 0.00 SEK
2019-05-21 - Årsstämma
2019-05-21 - Kvartalsrapport 2019-Q1
2019-02-22 - Bokslutskommuniké 2018
2018-10-26 - Kvartalsrapport 2018-Q3
2018-07-13 - Kvartalsrapport 2018-Q2
2018-05-18 - X-dag ordinarie utdelning ONCO 0.00 SEK
2018-05-17 - Årsstämma
2018-05-17 - Kvartalsrapport 2018-Q1
2018-02-22 - Bokslutskommuniké 2017
2017-11-15 - Kvartalsrapport 2017-Q3
2017-08-25 - Kvartalsrapport 2017-Q2
2017-05-18 - Årsstämma
2017-05-18 - Kvartalsrapport 2017-Q1

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Oncopeptides är ett bioteknikbolag som utvecklar läkemedel för svårbehandlade hematologiska sjukdomar. Bolaget använder sin PDC-plattform för att ta fram peptidlänkade läkemedel som selektivt levererar cellgifter in i cancerceller. Bolaget har läkemedel för kommersialisering, och har flera läkemedelskandidater under utveckling. Oncopeptides huvudkontor ligger i Stockholm.
2025-08-28 08:15:00

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.

Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) (Nasdaq Stockholm: ONCO) publishes disclosure document in connection with the Company’s new share issue with preferential rights for existing shareholders of approximately SEK 150 million, as resolved by the Board of Directors on 21 August 2025 by virtue of the authorization from the Annual General Meeting held on 22 May 2025 (the “Rights Issue”). The disclosure document has been registered with the Swedish Financial Supervisory Authority and is available at the Company’s website.

Disclosure document
In connection with the Rights Issue, the Company has prepared a disclosure document in accordance with Article 1.4 db of Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Prospectus Regulation”). The disclosure document has been prepared in accordance with the requirements of Annex IX to the Prospectus Regulation.
 
Today, Oncopeptides announces that the disclosure document has been registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is available on the Company’s website www.oncopeptides.com and on www.dnbcarnegie.se.
 
Preliminary timetable for the Rights Issue
The below timetable for the Rights Issue is preliminary and may be adjusted.
 

Record date for right to receive subscription rights28 August 2025
Trading in subscription rights1 – 10 September 2025
Subscription period1 – 15 September 2025
Trading in paid subscribed shares (BTA)1 – 22 September 2025
Announcement of the outcome of the Rights IssueAround 17 September 2025

 
Advisors
DNB Carnegie Investment Bank AB (publ) acts as Sole Global Coordinator and Joint Bookrunner in connection with the Rights Issue. Zonda Partners acts as Joint Bookrunner. Advokatfirman Vinge KB is legal adviser to the Company.